{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-018242","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2026-05-22T20:00:36+00:00","discovered_at":"2026-05-22T20:02:00.472042+00:00","generated_at":"2026-05-22T21:34:51.563555+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"confidence":"high","headline":"Moleculin Biotech ASCO abstract on Annamycin cardiac safety shows no cardiotoxicity in 90 patients","bullets":["Abstract accepted for poster at 2026 ASCO Annual Meeting (May 29–June 2, Chicago).","Pooled safety analysis of 90 Annamycin patients; median cumulative dose 660 mg/m2.","No significant LVEF change from baseline (mean diff -0.12%, p=0.84); no dose correlation.","CEO highlights potential to provide anthracycline therapy without cardiotoxicity limits.","Company's Phase 1b/2 AML study previously showed 50% CR and median OS of 12.39 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-018242","json":"https://secwatch.observer/filing/0001437749-26-018242.json","markdown":"https://secwatch.observer/filing/0001437749-26-018242.md","text":"https://secwatch.observer/filing/0001437749-26-018242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926018242/0001437749-26-018242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926018242/mbrx20260522_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T21:34:51.563555+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}